GPT and hepatotoxicity: In these trials, 30–40% of the patients experienced liver toxicity, mainly consisting of serious (grade ≥ 3 of the National Cancer Institute’s Common Terminology Criteria for Adverse Events, NCI-CTCAE) but transient elevation of transaminases (aspartate aminotransferases (AST) and alanine aminotransferases (ALT)).